Oxaliplatin
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Recombinant erythropoietin
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Pembrolizumab
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Venlafaxine
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Amikacin/ciprofloxacin/cotrimoxazole
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Febuxostat/HMG-CoA-reductase-inhibitors/proton-pump-inhibitors
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Ciclosporin
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Iguratimod/Warfarin
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Prednisolone
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Tozinameran
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Pembrolizumab
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Multiple drugs
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
COVID-19-vaccine/tamoxifen
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Multiple drugs
(Source: Reactions Weekly)
Source: Reactions Weekly - December 1, 2023 Category: Drugs & Pharmacology Source Type: research